Abstract: Allergic conjunctivitis (AC) is a common benign ocular surface disease. Numerous drugs are available for the clinical treatment of allergic conjunctivitis, but limitations such as slow onset of action, prolonged duration of administration, combination of drugs, prolonged duration of administration, and systemic adverse effects urgently call for the exploration of new and effective therapies for allergic conjunctivitis. In recent years, more and more new target drugs (Th2 inhibitors, anti-IgE antibodies, PDE4 inhibitors, receptor antagonists, glucocorticoid receptor agonists) as well as new modes of drug delivery (drug-eluting ophthalmoscopes, immunotherapy) have emerged. The efficacy and mechanism of action of the new target drugs are currently being studied in experimental animals. The marketed drug-eluting ophthalmoscopes are effective in relieving allergic symptoms, but the potential drug toxicity associated with the use of nanoparticles still needs further study. Immunotherapy has not yet been applied in the treatment of allergic conjunctivitis. Currently, there is no effective treatment option for allergic conjunctivitis, but the emergence of new target drugs and different modes of drug delivery has brought new hope for the treatment of allergic conjunctivitis.  (Int Rev Ophthalmol, 2025, 49:  62-68)

Key words: allergic conjunctivitis, anti-allergic medicine, therapy